Anti-iRhom2 antibodies
Rheumatoid Arthritis
Key Facts
About SciRhom
SciRhom is a private, preclinical-stage biotech developing novel humanized antibodies against the iRhom2/TACE axis, a master regulator of inflammation. Its platform aims to block several key cytokine pathways (e.g., TNF-alpha, IL-6) with a single agent, potentially offering superior efficacy and safety over current standards of care. The company is backed by a consortium of life science investors and led by a management team with extensive experience in antibody development and immunology. SciRhom's strategy is built on strong foundational science from Prof. Carl Blobel and protected by four patent families.
View full company profileAbout SciRhom
SciRhom is a private, preclinical-stage biotech developing novel humanized antibodies against the iRhom2/TACE axis, a master regulator of inflammation. Its platform aims to block several key cytokine pathways (e.g., TNF-alpha, IL-6) with a single agent, potentially offering superior efficacy and safety over current standards of care. The company is backed by a consortium of life science investors and led by a management team with extensive experience in antibody development and immunology. SciRhom's strategy is built on strong foundational science from Prof. Carl Blobel and protected by four patent families.
View full company profileAbout SciRhom
SciRhom is a private, preclinical-stage biotech developing novel humanized antibodies against the iRhom2/TACE axis, a master regulator of inflammation. Its platform aims to block several key cytokine pathways (e.g., TNF-alpha, IL-6) with a single agent, potentially offering superior efficacy and safety over current standards of care. The company is backed by a consortium of life science investors and led by a management team with extensive experience in antibody development and immunology. SciRhom's strategy is built on strong foundational science from Prof. Carl Blobel and protected by four patent families.
View full company profileOther Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |
| AX-158 | Artax Biopharma | Phase 2 |